News | Mammography | March 09, 2017

Solis Mammography Supports Texas Tomosynthesis Insurance Coverage Bill

HB1036 requires commercial providers to cover 3-D mammography

Solis Mammography, Texas, HB 1036, insurance coverage, 3-D mammography, tomosynthesis

March 9, 2017 — Solis Mammography, an independent provider of breast imaging services, believes that an educated patient makes the best decisions about their health. For this reason, Solis is urging support for Texas House Bill 1036 (HB1036), which if passed, would require all commercial insurance providers in Texas to cover digital breast tomosynthesis, also known as 3-D mammography, for breast cancer screening and diagnosis. House Bill 1036 was introduced on Jan. 1 by Texas Rep. Senfronia Thompson (D-Houston).

In November 2014, the American College of Radiology released this position statement on 3-D mammography: “To be clear; tomosynthesis (3-D) is no longer investigational. It has been shown to improve key screening parameters compared to (2-D) digital mammography. The college applauds the decision by the Centers for Medicare and Medicaid Services (CMS) to facilitate access to these exams by covering beneficiaries for tomosynthesis and urges private payers to do the same.”

In 2016, Blue Cross Blue Shield began its 3-D mammography coverage in Texas, and Cigna announced on Aug. 23, 2016, that they would begin providing coverage, becoming the first national private insurer to cover 3-D mammograms. United Healthcare recently announced a similar decision, adding 3-D mammography to its list of covered services for screening and diagnostic mammography effective Apr. 1.

The movement has shifted to other state legislatures who have already passed similar legislation to HB1036.  These states include Connecticut, Pennsylvania, Illinois and most recently New York. 

Research has proven the effectiveness of 3-D mammography, demonstrating increases in early detection of breast cancer by 54 percent and decreases in recall rates by 37 percent, as published in the American Journal of Roentgenology. Early detection contributes to long-term survival and also to quality of life, as masses found earlier will likely result in less aggressive treatment.

“In 2010, Solis Mammography’s chief medical officer, Dr. Steven Rose, presented the very first patient in the country to be diagnosed with 3-D alone to a [U.S.] Food and Drug Administration panel,” said James Polfreman, CEO of Solis Mammography. “In 2011, the FDA approved 3-D mammography, and in 2015, Medicare announced its decision to cover 3-D. It’s been another full two years since Medicare’s decision and we are still seeing too many women who have health insurance, but can’t get the best screening technology available because of a lack of coverage. This is simply not acceptable and women deserve better.”

For women whose insurance does not cover the cost of 3-D, out-of-pocket expenses can range from $50 to $150 for the added benefits and specificity of 3-D mammography.  These benefits include:

  • It provides around 60 layers of images, allowing radiologists to see cancers as early as stage zero;
  • It is better able to see behind dense breast tissue, which is important for breast cancer detection as not all breast cancers cause a lump in the breast that can be felt; and
  • It enhances the accuracy of breast cancer screenings by increasing specificity of early detection, reducing unnecessary callbacks (aka false positives) and reducing the need for unnecessary biopsies and other follow-up testing.

For more information: www.solismammo.com

Related Content

Therapixel Wins the Digital Mammography Challenge
News | Mammography | June 23, 2017
June 23, 2017 — French radiology technology company Therapixel was recently named the winner of the Digital Mammograp
MRI Plus Mammography Improves Detection of New Breast Cancer After Surgery
News | Breast Imaging | June 22, 2017
A new article published by JAMA Oncology compares outcomes for combined mammography and magnetic resonance imaging (MRI...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
ABS Clinical Director Alexandra Valencia, M.D.,  and consultant radiographer Gillian Clark using Insignia.

ABS Clinical Director Alexandra Valencia, M.D.,  and consultant radiographer Gillian Clark using Insignia.

News | Breast Imaging | June 12, 2017
ABS, one of the largest breast departments in the country, first signed with Insignia in 2010, and have confirmed a...
mammogram

Photo courtesy of Barco

News | Mammography | June 08, 2017
An analysis of breast cancer data revealed that many small breast cancers have an excellent prognosis because they are...
OCM images

These are sample OCM images (first row) and corresponding histology images (second row) of human breast tissue. The ground truth labels for the tissue type of these images are: (a) carcinoma, (b) lobule, (c) stroma, (d) adipose. Image courtesy of Sunhua Wan, Hsiang-Chieh Lee, Xiaolei Huang, Ting Xu, Tao Xu, Xianxu Zeng, Zhan Zhang, Yuri Sheikine, James L. Connolly, James G. Fujimoto, Chao Zhou

News | Clinical Study | June 07, 2017
According to a recent study, one in four women with breast cancer who opt for a breast-saving lumpectomy will need a...
News | Mammography | June 07, 2017
Hologic, Inc. announced that the Genius 3D Mammography exam is now the only mammogram that is FDA-approved as superior...
Feature | Women's Health | June 06, 2017 | By David A. Strahle, M.D.
Editor’s note: In this article, David A. Strahle, M.D., candidly shares how and why he and his team became involved...
breast tomosynthesis
News | Breast Imaging | June 06, 2017
Researchers at two leading U.S. breast centers recently completed a study which explored whether women attending...
concurrent-read cancer detection solution for digital breast tomosynthesis
News | Women's Health | June 06, 2017
Carolina Breast Imaging Specialists of Greenville, North Carolina today announced it is the first U.S. site to begin...
Overlay Init